Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19
Open Access
- 18 May 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 27 (6), 1071-1078
- https://doi.org/10.1038/s41591-021-01370-1
Abstract
Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are being deployed, but the global need greatly exceeds the supply, and different formulations might be required for specific populations. Here we report Day 42 interim safety and immunogenicity data from an observer-blinded, dose escalation, randomized controlled study of a virus-like particle vaccine candidate produced in plants that displays the SARS-CoV-2 spike glycoprotein (CoVLP: NCT04450004). The co-primary outcomes were the short-term tolerability/safety and immunogenicity of CoVLP formulations assessed by neutralizing antibody (NAb) and cellular responses. Secondary outcomes in this ongoing study include safety and immunogenicity assessments up to 12 months after vaccination. Adults (18–55 years, n = 180) were randomized at two sites in Quebec, Canada, to receive two intramuscular doses of CoVLP (3.75 μg, 7.5 μg, and 15 μg) 21 d apart, alone or adjuvanted with AS03 or CpG1018. All formulations were well tolerated, and adverse events after vaccination were generally mild to moderate, transient and highest in the adjuvanted groups. There was no CoVLP dose effect on serum NAbs, but titers increased significantly with both adjuvants. After the second dose, NAbs in the CoVLP + AS03 groups were more than tenfold higher than titers in Coronavirus 2019 convalescent sera. Both spike protein-specific interferon-γ and interleukin-4 cellular responses were also induced. This pre-specified interim analysis supports further evaluation of the CoVLP vaccine candidate.Keywords
Funding Information
- Medicago Inc
This publication has 59 references indexed in Scilit:
- Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigensClinical Immunology, 2014
- Virus-Specific Memory CD8 T Cells Provide Substantial Protection from Lethal Severe Acute Respiratory Syndrome Coronavirus InfectionJournal of Virology, 2014
- Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancerVaccine, 2014
- Taliglucerase alfa: An enzyme replacement therapy using plant cell expression technologyMolecular Genetics and Metabolism, 2014
- Lack of Peripheral Memory B Cell Responses in Recovered Patients with Severe Acute Respiratory Syndrome: A Six-Year Follow-Up StudyThe Journal of Immunology, 2011
- Follicular Helper CD4 T Cells (TFH)Annual Review of Immunology, 2011
- Targeting the TLR9–MyD88 pathway in the regulation of adaptive immune responsesEmerging Therapeutic Targets, 2010
- The production of hemagglutinin‐based virus‐like particles in plants: a rapid, efficient and safe response to pandemic influenzaPlant Biotechnology Journal, 2010
- Influenza virus‐like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in micePlant Biotechnology Journal, 2008
- Two classes of short interfering RNA in RNA silencingThe EMBO Journal, 2002